drugset

drugset / Trial / NCT05888402

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

NCT05888402 ↗

Phase 2 Active not recruiting 50 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences Shanghai Junshi Bioscience Co., Ltd. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a Phase II study to evaluate the clinical efficacy and safety of Toripalimab combined with chemoradiotherapy for large-volume local advanced non-small cell lung cancer

Timeline

Start: 2023-01-20
Primary completion: 2024-10-08
Completion: 2026-03-20

Publications

Wang Y, Deng L, Wang J, Zhang T, Wang W, Wang X, Liu W, Wu Y, Lv J, Feng Q, Zhou Z, Wang J, Wang L, Wang Z, Bi N. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study). Front Immunol. 2024 Jan 15;14:1341584. doi: 10.3389/fimmu.2023.1341584. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Toripalimab	Monoclonal antibody	240 mg	—

Indications